DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vlhmzc/randd_trends_auti) has announced the addition of the "R&D Trends: Autism Spectrum Disorders - Pipeline Growth Reflects Increasing Interest in Autism" report to their offering.
This report reviews the key trends in the autism spectrum disorders pipeline. The analysis is intended to support R&D decision-making by evaluating the dynamics of the pipeline and hypothesizing future treatments of autism spectrum disorders.
The autism spectrum disorders (ASDs) market is a challenging one to penetrate; since 2006 only two products have been successful in entering this marketplace: Risperdal (risperidone; Johnson & amp; Johnson) and Abilify (aripiprazole; Bristol-Myers Squibb). However, as additional agents near the market, increasing interest in ASDs has led to a sizable growth in the clinical pipeline.
Scope
- Overview of drugs in late- and early-stage clinical development for autism spectrum disorders.
- Identification of the target product profile for future autism spectrum disorders treatments.
- Summary of clinical trial design in autism spectrum disorders including exploration of key endpoints and assessment methodology.
- Identification of key challenges associated with the conduct of clinical trials in autism spectrum disorders.
- Exploration of future treatment in autism spectrum disorders including the development of personalized treatments and the use of biomarkers.
Highlights
- The autism spectrum disorders (ASDs) pipeline remains sparse relative to other conditions that are treated with psychotropic medications. The unknown etiology of ASDs poses a fundamental challenge to the therapeutic discovery process. However, the pipeline growth is encouraging and reflects an increased interest in ASDs.
- The two approved therapies for the management of autism spectrum disorders both target the symptoms of irritability. The comparator therapy identified by Datamonitor is Risperdal (risperidone; Johnson & Johnson) as it was the first to be approved in this indication, demonstrates a strong efficacy profile, and is regarded as a first-line therapy.
- Key challenges associated with the conduct of clinical trials in autism spectrum disorders are: the unknown etiology of the disorders and heterogeneous symptomology. Communication and language impairments commonly associated with autism spectrum disorders further compound these challenges
Questions examined include:
- How many drugs are in clinical development for the treatment of autism spectrum disorders? What deters companies from investing in this area?
- What symptoms and mechanisms of action are most frequently targeted? What key companies are involved in the pipeline?
- What is the target product profile and most appropriate comparator therapy?
- What are the key challenges in conducting clinical trials in autism spectrum disorders?
- How is the treatment of autism spectrum disorders likely to evolve over the next 10 to 20 years?
Companies Mentioned Include:
- Celgene Corporation
- Commerzbank AG
- Forest Laboratories Inc.
- GlaxoSmithKline Plc
- Hutchison 3G UK Limited
- Informa plc
- Janssen Pharmaceuticals Inc.
- LVMH Moet Hennessy Louis Vuitton SA
- Wolters Kluwer nv
For more information visit http://www.researchandmarkets.com/research/vlhmzc/randd_trends_auti